drugset / Trial / NCT01165554

Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

NCT01165554

NaSingle-groupOpen-labelDiagnostic

Summary

To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.

Timeline

Start
2010-05
Primary completion
2011-11
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Flutemetamol Diagnostic / imaging agent 111 mbq Intravenous
Subject Flutemetamol Diagnostic / imaging agent 370 mbq Intravenous

Indications

No indication recorded.